These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 9439509

  • 21. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.
    Steffan JS, Thompson LM.
    Expert Opin Ther Targets; 2003 Apr; 7(2):201-13. PubMed ID: 12667098
    [Abstract] [Full Text] [Related]

  • 22. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.
    Davies SW, Turmaine M, Cozens BA, Raza AS, Mahal A, Mangiarini L, Bates GP.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):971-9. PubMed ID: 10434295
    [Abstract] [Full Text] [Related]

  • 23. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?
    Kennedy L, Shelbourne PF.
    Hum Mol Genet; 2000 Oct 12; 9(17):2539-44. PubMed ID: 11030759
    [Abstract] [Full Text] [Related]

  • 24. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?
    Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O.
    Mech Ageing Dev; 2006 Feb 12; 127(2):208-12. PubMed ID: 16274727
    [Abstract] [Full Text] [Related]

  • 25. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP.
    Cell; 1996 Nov 01; 87(3):493-506. PubMed ID: 8898202
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The early cellular pathology of Huntington's disease.
    Li XJ.
    Mol Neurobiol; 1999 Nov 01; 20(2-3):111-24. PubMed ID: 10966117
    [Abstract] [Full Text] [Related]

  • 28. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice.
    Yu ZX, Li SH, Nguyen HP, Li XJ.
    Hum Mol Genet; 2002 Apr 15; 11(8):905-14. PubMed ID: 11971872
    [Abstract] [Full Text] [Related]

  • 29. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
    Schiefer J, Landwehrmeyer GB, Lüesse HG, Sprünken A, Puls C, Milkereit A, Milkereit E, Kosinski CM.
    Mov Disord; 2002 Jul 15; 17(4):748-57. PubMed ID: 12210870
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B, Schiefer J, Sass C, Kosinski CM, Kochanek S.
    J Gene Med; 2008 Mar 15; 10(3):269-79. PubMed ID: 18067195
    [Abstract] [Full Text] [Related]

  • 34. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.
    Liu KY, Shyu YC, Barbaro BA, Lin YT, Chern Y, Thompson LM, James Shen CK, Marsh JL.
    Hum Mol Genet; 2015 Mar 15; 24(6):1602-16. PubMed ID: 25398943
    [Abstract] [Full Text] [Related]

  • 35. Molecular aspects of Huntington's disease.
    Walling HW, Baldassare JJ, Westfall TC.
    J Neurosci Res; 1998 Nov 01; 54(3):301-8. PubMed ID: 9819135
    [Abstract] [Full Text] [Related]

  • 36. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
    Li SH, Li XJ.
    Trends Genet; 2004 Mar 01; 20(3):146-54. PubMed ID: 15036808
    [Abstract] [Full Text] [Related]

  • 37. RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells.
    Doi H, Okamura K, Bauer PO, Furukawa Y, Shimizu H, Kurosawa M, Machida Y, Miyazaki H, Mitsui K, Kuroiwa Y, Nukina N.
    J Biol Chem; 2008 Mar 07; 283(10):6489-500. PubMed ID: 18167354
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.
    Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ.
    J Neurosci; 2000 Jul 01; 20(13):5115-23. PubMed ID: 10864968
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.